Crohn disease: epidemiology, diagnosis, and management

JD Feuerstein, AS Cheifetz - Mayo Clinic Proceedings, 2017 - Elsevier
Crohn disease is a chronic idiopathic inflammatory bowel disease condition characterized
by skip lesions and transmural inflammation that can affect the entire gastrointestinal tract …

Ulcerative colitis: epidemiology, diagnosis, and management

JD Feuerstein, AS Cheifetz - Mayo Clinic Proceedings, 2014 - Elsevier
Ulcerative colitis is a chronic idiopathic inflammatory bowel disease characterized by
continuous mucosal inflammation that starts in the rectum and extends proximally. Typical …

[HTML][HTML] Artificial intelligence applications in inflammatory bowel disease: emerging technologies and future directions

J Gubatan, S Levitte, A Patel, T Balabanis… - World journal of …, 2021 - ncbi.nlm.nih.gov
Inflammatory bowel disease (IBD) is a complex and multifaceted disorder of the
gastrointestinal tract that is increasing in incidence worldwide and associated with …

Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis

KJ Khan, MC Dubinsky, AC Ford… - Official journal of the …, 2011 - journals.lww.com
OBJECTIVES: There remains controversy regarding the efficacy of thiopurine analogs
(azathioprine (AZA) and 6-mercaptopurine (6-MP)), methotrexate (MTX), and cyclosporine …

Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease: a systematic review and meta-analysis

J Costa, F Magro, D Caldeira, J Alarcao… - Inflammatory bowel …, 2013 - academic.oup.com
Background We systematically reviewed infliximab benefit in reducing hospitalizations
and/or major surgery rates in patients with inflammatory bowel disease (IBD). Methods A …

the practical management of acute severe ulcerative colitis

D Seah, P De Cruz - Alimentary pharmacology & therapeutics, 2016 - Wiley Online Library
Background Acute severe ulcerative colitis (ASUC) is a life‐threatening condition for which
optimal management strategies remain ill‐defined. Aim To review the evidence regarding …

Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future

D Pugliese, C Felice, A Papa, A Gasbarrini… - Expert Review of …, 2017 - Taylor & Francis
Introduction: Anti TNF-α agents have become a significant advance in the management of
ulcerative colitis, proving to induce, with rapid onset, clinical and endoscopic remission …

Clinical practice guideline for the surgical management of Crohn's disease

S Strong, SR Steele, M Boutrous… - Diseases of the Colon …, 2015 - journals.lww.com
The American Society of Colon and Rectal Surgeons is dedicated to ensuring high-quality
patient care by advancing the science, prevention, and management of disorders and …

Meta‐analysis: pre‐operative infliximab treatment and short‐term post‐operative complications in patients with ulcerative colitis

Z Yang, Q Wu, K Wu, D Fan - Alimentary pharmacology & …, 2010 - Wiley Online Library
Aliment Pharmacol Ther 31, 486–492 Summary Background Infliximab was approved for
use in ulcerative colitis in recent years. It has been debated if infliximab increases the risk of …

[HTML][HTML] Immunosuppressive therapies for inflammatory bowel disease

T Zenlea, MA Peppercorn - World journal of gastroenterology: WJG, 2014 - ncbi.nlm.nih.gov
Inflammatory bowel disease (IBD) is comprised of Crohn's disease and ulcerative colitis,
both chronic inflammatory intestinal disorders of unknown etiology characterized by a …